Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Acute Myocardial Infarction
NCT05887830Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial in ST elevation myocardial infarction (STEMI) comparing Nivolumab with Placebo (2 arms). Primary endpoints: Difference in Infarct size/Left Ventricular mass% at 3 months and Incidence of adverse events at 3 months. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05887830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887830.